Benefits
Recurrent strep throat and tonsillitis prevention (K12)
S. salivarius K12 lozenges have multiple RCTs showing reduced recurrent streptococcal pharyngitis (strep throat) and tonsillitis episodes in children with history of recurrent infection. A 2014 RCT in 56 children showed K12 use (90 days) reduced strep throat episodes by 90% and tonsillitis episodes by 80% over the following year — replacing prophylactic antibiotics.
Halitosis (bad breath) reduction
S. salivarius K12 displaces volatile sulfur compound (VSC)-producing bacteria responsible for halitosis. Clinical trials show K12 lozenges (1 billion CFU/day) significantly reduce VSC levels, breath odor (organoleptic scoring), and patient-reported halitosis severity within 1 week. Effects persist 2–3 weeks after discontinuation.
Dental caries reduction (M18)
S. salivarius M18 produces salivaricin M, which specifically inhibits Streptococcus mutans (the primary cariogenic bacterium). RCTs in children show M18 lozenges reduce S. mutans counts by 30–60%, reduce dental plaque, and reduce caries incidence over 6–12 months. Particularly useful for children with high caries risk.
Recurrent acute otitis media reduction in children
S. salivarius K12 via mouth lozenge or nasal spray reduces middle ear infections in children prone to recurrent acute otitis media (AOM). Mechanism: K12 colonizes the nasopharynx and Eustachian tube area, suppressing pathogen colonization (Streptococcus pneumoniae, Haemophilus influenzae) before they spread to middle ear.
Mechanism of action
Salivaricin production — bacteriocin-like inhibitory substances (BLIS)
S. salivarius K12 produces salivaricins A2 and B that inhibit Group A Streptococcus, Streptococcus pneumoniae, and other oropharyngeal pathogens. M18 strain produces salivaricin M, A2, B, and 9 — most active against S. mutans. These bacteriocins target similar bacterial species (related Streptococcus genera) without affecting commensal flora.
Niche occupation in oral cavity and throat
Both K12 and M18 colonize tongue, gum line, and oropharynx after lozenge dissolution. Continuous occupation of these niches prevents pathogen establishment — competitive exclusion through space and nutrient competition. Colonization is transient (weeks) so daily dosing is needed for ongoing protection.
VSC-producing bacteria displacement
Halitosis is primarily caused by anaerobic bacteria (Solobacterium moorei, Atopobium, Fusobacterium) producing volatile sulfur compounds (hydrogen sulfide, methyl mercaptan). K12 displaces these species through niche competition and direct salivaricin inhibition.
Adhesion to oral epithelium
S. salivarius expresses surface adhesins (similar in structure to S. mutans adhesins) that bind oral epithelial receptors and salivary glycoproteins. Strong adhesion enables niche persistence beyond simple lozenge transit.
Clinical trials
Open-label controlled trial. Children with history of recurrent strep pharyngitis received K12 lozenge (1 billion CFU/day) for 90 days; control group received standard care. Both groups followed for next year of strep episodes.
65 children (39 K12, 26 control), age 3–13.
Strep throat episodes/year: K12 group 0.4 vs. control 4.0 (90% reduction). Antibiotic prescriptions: 75% reduction. Tonsillitis episodes: 80% reduction. Acute otitis media: 78% reduction. K12 well-tolerated with no adverse events.
Crossover, randomized, double-blind, placebo-controlled trial. Subjects with halitosis received K12 lozenges or placebo lozenges, 3 lozenges/day for 1 week each, with washout.
23 adults with diagnosed halitosis (organoleptic score ≥2).
VSC measurements (Halimeter® hydrogen sulfide detection) reduced by 85% with K12 vs. baseline; placebo had minimal effect. Organoleptic breath scores reduced by ~60%. Effects persisted 2 weeks after discontinuation in 50% of subjects.
12-month, randomized, double-blind, placebo-controlled trial. Children with high caries risk received M18 lozenge (1 billion CFU/day) or placebo.
100 children with high caries risk.
S. mutans counts reduced by ~60% in M18 group at 6 months. New caries development reduced by ~40% at 12 months. Plaque index also significantly improved.